Form 4: Denali CEO Ryan Watts Gifts 50,000 Shares to Charity
Insider Transaction Report
Denali Therapeutics CEO Ryan Watts reported a charitable contribution of 50,000 shares of common stock.
Summary
- Ryan J. Watts, President and CEO of Denali Therapeutics Inc. (DNLI), reported a disposition of 50,000 shares of common stock.
- The transaction, dated September 3, 2025, was an in-kind charitable contribution to a donor-advised fund.
- The shares were disposed of at a price of $0, consistent with a gift.
- Following this transaction, Mr. Watts directly beneficially owns 253,071 shares, which include 177,940 unvested Restricted Stock Units (RSUs).
- Additionally, 2,152,604 shares are indirectly beneficially owned through the Watts Family 2015 Trust, for which Mr. Watts serves as trustee.
- The transaction was made pursuant to a Rule 10b5-1(c) plan.
Sentiment
Score: 6
Explanation: The filing reports a charitable contribution of shares by the CEO, which is generally viewed neutrally to slightly positively as it's not a sale for personal gain. It does not reflect on the company's operational or financial performance.
Positives
- The transaction is a charitable contribution, which can reflect positively on the executive's philanthropic activities.
- The disposition is not a sale for personal gain, mitigating concerns about opportunistic insider selling.
Negatives
- A reduction in direct share ownership, even if for charitable purposes, slightly decreases the executive's direct equity stake.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan | Transaction executed under a Rule 10b5-1(c) plan, indicating a pre-arranged schedule for stock transactions. | 09/03/2025 | Enhances transparency and mitigates concerns about opportunistic insider trading. |
Related Party Transactions
- Indirect beneficial ownership of 2,152,604 shares is held by the Watts Family 2015 Trust, for which Ryan J. Watts serves as trustee.
Stakeholder Impact
- Shareholders: A minor reduction in the CEO's direct ownership, but the charitable nature and 10b5-1 plan mitigate negative perceptions. Overall impact is minimal.
Key Dates
| Date | Description |
|---|---|
| 07/07/2015 | Date of the Watts Family 2015 Trust establishment. |
| 09/03/2025 | Date of the charitable contribution transaction. |
| 09/05/2025 | Date the Form 4 was signed. |
Recommendation
holdThis Form 4 reports a charitable contribution of shares by the CEO and does not contain information related to the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is a routine insider disclosure.
Keywords
Denali Therapeutics, DNLI, Ryan J. Watts, Insider Transaction, Form 4, Charitable Contribution, CEO, Stock Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.